ACTA2 Alliance team at the ACMG Conference 2026

At #ACMGtg26, we connected with 3,000+ providers and spoke with 100+ about #ACTA2 & #MSMDS. Huge thanks to the amazing team making this possible 👏💙 #RareDisease #Genetics @theacmg.bsky.social

Learn more about adaptive sampling in our latest #Nanopore Know-How: nanoporetech.com/blog/guided-by-data-adap... #ACMGtg26

24 hours. One genome. Real impact.

See how rapid whole‑genome Oxford Nanopore sequencing could accelerate clinical research in NICUs — because when time matters, answers can’t wait.

Watch the webinar: https://bit.ly/4dcSiPe #ACMGtg26

For Research Use Only.

At #ACMGtg26, Chad Pollard will share how they are unlocking methylation profiles behind disease with direct Oxford Nanopore sequencing. Join him to learn how these insights could transform how we research and identify rare genetic diseases. https://bit.ly/3OEPujV

At #ACMGtg26, Tjakko van Ham will discuss implementing Oxford Nanopore sequencing in clinical genetics — including comprehensive variant calling & methylation analysis in unresolved rare disease, & ultra-rapid WGS from sample to variants in 24 hours. https://bit.ly/3OLC0CR

Wendy Chung has identified the genetic basis of ~60 rare diseases.

At #ACMGtg26, she’ll share how they characterised previously inaccessible regions of the genome – expanding the frontier of rare disease discovery. https://bit.ly/4rdk8OX

What if an end to the diagnostic odyssey was in reach?

Join our symposium at #ACMGtg26 to hear from leading speakers who are moving closer to making this possible, using Oxford Nanopore sequencing to unlock multiomic insights. https://bit.ly/3MPyTcl